Consumer health giant Kenvue delivered higher quarterly earnings and revenue, providing early validation for management's restructuring and brand reinvestment initiatives.

Haleon shares slumped after the consumer healthcare giant trimmed its full-year guidance, driven by softening demand and shifting retail patterns in key markets.

A dramatic shift in federal oversight permitting certain unapproved peptides has rattled pharmaceutical giants while igniting a boom for alternative wellness markets.

GSK shares fell sharply after disappointing vaccine sales raised investor concerns over slowing demand for flagship treatments and intensifying sector competition.

GSK projects its oncology pipeline will nearly double next year, riding a wave of targeted acquisitions aimed at countering upcoming patent expirations.

Bayer has gained regulatory clearance in China for its novel stroke-prevention medication, capturing a global first-in-class approval as it rebuilds its cardiovascular pipeline.

Despite persistent consumer anxiety and pessimistic headlines, hard economic data and corporate balance sheets reveal surprising structural resilience across key sectors.